Meeting report: innovations in prostate cancer research.

The incidence of prostate cancer has increased with serum prostate-specific antigen (PSA) screening. Although organ-confined prostate cancer can be cured by surgery and/or radiation therapy, metastatic disease cannot. Androgen ablation in this setting has long been recognized as effective, but tumors almost invariably relapse over time; unfortunately, outcome of patients with metastatic androgen-independent disease remains poor despite incremental improvements in chemotherapy. The purpose of this ‘‘Special AACR Conference in Prostate Cancer’’ was (a) to provide a specialized forum for presentation of state-of-the-art diseasespecific research; (b) to attract innovative investigators from other fields; and (c) to introduce new cutting-edge technologies into prostate cancer basic, translational, and clinical investigation.